



MOREPEN



Press Release

Morepen reports a turnaround performance in second quarter

Profit Jumps by 940%, income from operations by 24% and Exports by 52% in Q2 FY 2015-16

New Delhi, November 4/5, 2015: Morepen Laboratories Ltd. has reported a steep jump of over 940% in its bottom line backed by an impressive all-round improvement in sales revenue of its various divisions in the second quarter (Q2) ended September 30, 2015.

Morepen's **profit after tax (PAT)** in Q2 of financial Year 2015-16 stood at Rs.3.22 crore up from Rs. 31 lakhs in the corresponding quarter of the previous financial year. The company's **net income from operations** rose by 24 per cent in Q2 at Rs. 113.00 crore from Rs.91.18 crore and **EBIDTA** grew by 55% at Rs. 16.06 crore from Rs. 10.35 crore in the corresponding quarter of the previous fiscal. The cash surplus (**EBDA**) has also shown a significant rise of 49% at Rs. 12.74 crore (Rs.8.52 Crore).

Speaking on the spectacular turnaround reported by the company in the second quarter, Mr. Sushil Suri, Chairman & Managing Director, Morepen Laboratories Ltd, said, *"Morepen has a niche in the API business. Our cost reduction efforts coupled with continuous investments in R&D yielded rich dividends for the company as it attained a strong hold in the international markets, which eventually reflected positively on financial front in the current fiscal."*

A major portion of the growth in Q2 has come from exports business at Rs. 51.55 crore (Rs. 33.92 crore), an increase of 52%. Amongst various business segments, the Active Pharmaceutical Ingredients (API)/ Bulk Drugs segment's contribution in total sales continued to remain at the top with revenue of Rs. 69.52 crore in Q2 FY 2015-16, up by 37 per cent from Rs. 50.59 crore in corresponding quarter of the previous FY. Within the bulk drug's segment, Atorvastatin's business stood at Rs. 11.31 crore and Loratadine at Rs. 29.46 crore, registering a growth of 79% and 37% respectively.

The Home Diagnostics business with a sales revenue of Rs. 16.08 crore in Q2 FY 2015-16 (Rs. 13.75 crore) is another big contributor to the upsurge in the overall performance. Blood Glucometers and BP Monitors, used for measuring blood sugar and blood pressure in human body, are the main force driving Home Diagnostics sales of the company in the current fiscal. These high-end devices alone have recorded sales revenue of Rs. 10.93 Crore in Q2 FY 2015-16. The company's brands "Gluko One" and "BP One" are amongst the top

Morepen Laboratories Limited

Corp. Off.: 4th Floor, Antriksh Bhawan, 22 K.G. Marg, New Delhi -110 001, INDIA
Tel.:+91-11-23324443, E-mail: corporate@morepen.com, Website: www.morepen.com
CIN NO. L24231HP1984PLC006028

Plant & Regd. Off.: Morepen Village, Malkumajra, Nalagarh Raod, Baddi, Distt. Solan (H.P.) 173 205
Tel.: +91-1795-266401-03, 244590, Fax : +91-1795-244591, E-mail: plants@morepen.com

